In clinical practice, CD38-targeted therapy using CD38 monoclonal antibodies has been performed in patients with hematologic malignancies such as multiple myeloma (MM), which highly expresses CD38 on their malignant cells [139,140,141,142,143]. The gene discussed is CD38; the disease is plasma cell myeloma.